Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

CymaBay Therapeutics, Inc. (CBAY)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
8.55+0.02 (+0.23%)
At close: 04:00PM EST
8.54 -0.01 (-0.12%)
After hours: 07:56PM EST
Advertisement

CymaBay Therapeutics, Inc.

7575 Gateway Boulevard
Suite 110
Newark, CA 94560
United States
510 293 8800
https://www.cymabay.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees59

Key Executives

NameTitlePayExercisedYear Born
Mr. Sujal A. ShahPres, CEO & Director873.87kN/A1973
Dr. Dennis D. Kim M.B.A., M.D., MBAChief Medical Officer406.11kN/A1970
Mr. Lewis J. Stuart B.A., BA, M.B.A., MBAChief Commercial Officer378.79kN/A1959
Mr. Daniel MenoldVP of Fin.N/AN/A1970
Dr. Charles A. McWherter Ph.D.Sr. VP, Pres of R&D and Chief Scientific OfficerN/AN/A1955
Mr. Paul T. QuinlanGen. Counsel, Chief Compliance Officer & Corp. Sec.N/AN/A1963
Mr. Ken BoehmSr. VP of HRN/AN/AN/A
Mr. Patrick J. O'MaraSr. VP of Bus. Devel.N/AN/A1961
Dr. Robert L. MartinSr. VP of Manufacturing & Nonclinical Devel.N/AN/A1962
Ms. Klara A. Dickinson-EasonChief Regulatory & Quality Assurance OfficerN/AN/A1968
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of primary biliary cholangitis (PBC), as well as has completed Phase 2b clinical study to treat patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, which is in Phase 2a clinical study for the disease/condition of hypoglycemia in type 1 diabetics. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.

Corporate Governance

CymaBay Therapeutics, Inc.’s ISS Governance QualityScore as of February 1, 2023 is 9. The pillar scores are Audit: 9; Board: 6; Shareholder Rights: 6; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement